The New Jersey Attorney General plans to finalize new limits on payments and other benefits that New Jersey licensed prescribers may accept from pharmaceutical manufacturers, although the expected final rule is less restrictive than the proposed rule published by the state in October 2017. This alert highlights key provisions of the final rule: (1) a US$10,000 annual aggregate cap on each prescriber's payments for services from all drug manufacturers, but with new exceptions; (2) a US$15 per-meal limit on promotional meals, but no limit on the frequency of the meals as proposed; and (3) a new exception for recruitment expenses.